What is the current stock price of Prime Medicine, Inc. (PRME)?

As of the latest market data, Prime Medicine, Inc. (PRME) is trading at $3.43. The stock has seen a loss of -2.28% today.

Does Prime Medicine, Inc. (PRME) pay a dividend?

Based on current data, Prime Medicine, Inc. does not have a confirmed active dividend policy.

What is the market cap of Prime Medicine, Inc.?

The current market capitalization of Prime Medicine, Inc. (PRME) is approximately unavailable.

PRME

Prime Medicine, Inc.·Healthcare

3.43

2.279%(−0.08)

Market Closed

3.70

7.872%(+0.27)

After Hours

Last Updated: — ET

52W L: $1.1152W H: $6.94

PRME NEWS

defenseworld.net

Mar 25

Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME)

Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Risk and Volatility Prime Medicine has a

defenseworld.net

Mar 25

Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)

Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends. Earnings and Valuation This table compares Athira

defenseworld.net

Mar 20

Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)

Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of

defenseworld.net

Mar 19

Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA) Head to Head Review

Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations. Earnings and Valuation This table compares Athira

defenseworld.net

Mar 16

Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey

Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation. Valuation and Earnings This table compares Prime

defenseworld.net

Mar 9

Athira Pharma (NASDAQ:LONA) vs. Prime Medicine (NASDAQ:PRME) Financial Analysis

Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends. Profitability This table compares Athira Pharma and

Company Profile

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

214

IPO Date

2022-10-20

Beta

2.67

Websitewww.primemedicine.com↗